Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 3, 2013, Pages 1725-1729

  Tarhan, Mustafa Oktay ^a   Gonel, Ataman ^a   Kucukzeybek, Yuksel ^a   Erten, Cigdem ^a   Cuhadar, Serap ^a   Yigit, Seyran Ceri ^a   Atay, Aysenur ^a   Somali, Isil ^a   Dirican, Ahmet ^a   Demir, Lutfiye ^a   Koseoglu, Mehmet ^a  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

Author keywords

Ca15 3; Circulating tumor cells; Metastatic breast cancer; Turkey

Indexed keywords

EID: 84880419049     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.3.1725     Document Type: Article

References (34)

1. Allard WJ, Matera J, Miller MC, et al (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in the healthy subjects or patients with non-malignant diseases. Clin Cancer Res, 10, 6897-904.
2. Andreopoulou E, Hortobagyi GN (2008). Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol, 26, 3660-2.
3. Asworth TR (1869). A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J, 14, 146-7.
4. Bidard FC, Hajage D, Bachelot T, et al (2012). Assesment of circulating tumor cells and serum markers for progression free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res, 14, 29.
5. Bosl GJ, Motzer RJ (1977). Testicular germ cell cancer. N Engl J Med, 337, 242-51.
6. Budd GT, Cristofanilli M, Ellis MJ, et al (2006). Circulating tumor cells versus imaging predicting overal survival in metastatic breast cancer. Clin Cancer Res, 12, 6403-9.
7. Colomer R, Ruibal A, Genolla J, et al (1989). Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and non-malignant disease. Breast Cancer Res Treat, 13, 123-33.
8. Colomer R, Ruibal A, Salvador L (1989). Circulating tumor marker levels in advanced breast carcinoma correla te with the extent of melastatic disease. Cancer, 64, 1674-81.
9. Consoli F, Grisanti S, Amorosso V, et al (2011). Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial. Tumori, 97, 7377-742.
10. Cristofanilli M, Broglio KR, Guarneri V, et al (2007). Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer, 6, 471-9.
11. Cristofanilli M, Budd GT, Ellis MJ, et al (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Eng J Med, 351,781-91.
12. Cristofanilli M, Hayes DF, Budd GT, et al (2005). Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol, 23, 1420-30.
13. Dawood S, Broglio KR, Valero V, et al (2008). Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. Cancer, 113, 2422-30.
14. De Giorgi U, Valero V, Rohren E, et al (2009). Circulating tuöor cells and (18F) fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol, 27, 3303-11.
15. De La Lande B, Hacene K, Floiras J-L, et al (2002). Prognostic value of CA 15-3 kinetics for metastatic breast cancer. Int J Biol Markers, 17, 231-8.
16. Duffy MJ (2001). Carcinoembriyonik antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem, 47, 624-30.
17. Fehm T, Muller V, Alix Panabieres C, et al (2008). Micrometastatic spread and breast cancer detection and molecular characterization and clinical relevance. Breast Cancer Res, 10, 1.
18. Fisher Pm, Hancock BW (1997). Gestational trophoblastic disease and their treatment. Cancer Treat Rev, 23, 1-16.
19. Giuliano M, Giordano A, Jackson S, et al (2011). Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first line systemic treatment. Breast Cancer Res, 13, 67.
20. Harris L, Fritsche H, Mennel R, et al (2007). American Society of Clinical Oncology 2007 update of recommendations fort he use of tumor markers in breast cancer. J Clin Oncol, 25, 5287-312.
21. Hayes DF, Cristofanilli M, Budd GT (2006). Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression free and overal survival. Clin Cancer Res, 12, 4218-24.
22. Jacob K, Sollier C, Jabado N (2007). Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics, 4, 741-56.
23. Kallioniemi O, Oksa H, Aaran R, et al (1988). Serum CA 15 - 3 assay in the diagnosis and follow up of breast cancer. Br J Cancer, 58, 213-5.
24. Lang JE, Mosalpuria K, Cristofanilli M, et al (2009). HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancre. Breast Cancer Res Treat, 113, 501-7.
25. Parker C (2004). Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol, 5, 101-6.
26. Pierga J-Y, Hajage D, Bachelot T, et al (2012). High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Annals of Oncol, 23, 618-24.
27. Rack BK, Schindlbeck C, Schneeweiss A, et al (2008). Prognostic relevance of circulating tumor cells in peripheral blood of breast cancer patients before and after adjuvant chemotherapy: the german success trial. J Clin Oncol, 26, 7.
28. Ruibal A, Colomer R, Genolla J (1987). Prognostic value of CA 15-3 serum levels in patients having breast cancer. Horm Metab, 1,11-5.
29. Rustin GJS (2003). Use of CA125 to ases response to new agents in ovarian cancer trials. J Clin Oncol, 21, 187-93.
30. Safi F, Kohler I, Rottinger E, et al (1989). Comparison of CA 15 - 3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers, 4, 207-14.
31. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
32. Tampellini M, Berutti A, Gerbino A, et al (1997). Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer, 75, 698- 702.
33. Tewes M, Aktas B, Welt A, et al (2009). Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat, 115, 581-90.
34. Tokudome N, Ito Y, Takahashi S, et al (2011). Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients. Breast Cancer, 18, 195-202.